Abstract
Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.
This is a preview of subscription content, log in via an institution to check access.
References
Ashour AE, Turnquist HR, Singh RK, Talmadge JE, Solheim JC. CCL21-induced immune cell infiltration. Int Immunopharmacol. 2007;7(2):272–6. Epub 2006 Nov 13.
Baratelli F, et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med. 2008;6(1):38.
Coppola D, Mule JJ. Ectopic lymph nodes within human solid tumors. J Clin Oncol. 2008;26(27):4369–70.
Cyster J. Chemokines and cell migration in secondary lymphoid organs. Science. 1999;286:2098–102.
Dieu-Nosjean MC, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410–7.
Flanagan K, et al. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol. 2004;231(1–2):75–84. Epub 2005 Jan 21.
Friedman RS, et al. Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol. 2006;7(10):1101–8. Epub 2006 Sep 10.
Gollmer K, et al. CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood. 2009;114(3):580–8. Epub 2009 May 18.
Kirk C, et al. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 2001a;61(24):8794–802.
Kirk CJ, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 2001b;61(5):2062–70.
Lapteva N, et al. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009;17(9):1626–36. Epub 2009 Jun 16.
Liang CM, et al. Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity. J Virol. 2007;81(17):9502–11. Epub 2007 Jun 13.
Miller PW, et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther. 2000;11(1):53–65.
Novak L, et al. Characterization of the CCL21-mediated melanoma-specific immune responses and in situ melanoma eradication. Mol Cancer Ther. 2007;6(6):1755–64.
Sharma S, et al. Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with Interleukin 7 / Herpes Simplex Thymidine Kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Ther. 1997;4:1361–70.
Sharma S, et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000;164(9):4558–63.
Tatsumi T, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003;63(19):6378–86.
Turnquist HR, Lin X, Ashour AE, Hollingsworth MA, Singh RK, Talmadge JE, Solheim JC. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int J Oncol. 2007;30(3):631–9.
Vicari AP, et al. Antitumor effects of the Mouse Chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol. 2000;165:1992–2000.
Yang SC, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res. 2004;10(8):2891–901.
Yang SC, et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res. 2006;66(6):3205–13.
Yousefieh N, et al. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron. 2009;6:6.
Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology. 1993;25(4):338–43.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science + Business Media, New York (outside the USA)
About this entry
Cite this entry
Sharma, S. et al. (2013). CCL21. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6613-0_33-4
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6613-0_33-4
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-6613-0
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences